Cesamet™ (nabilone) — Competitive Intelligence Brief

Cesamet™ (nabilone) (Cesamet™ (nabilone)) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Synthetic cannabinoid. Area: Oncology, Anesthesia.

marketed Synthetic cannabinoid CB1 and CB2 cannabinoid receptors Oncology, Anesthesia Small molecule

Target snapshot

Cesamet™ (nabilone) (Cesamet™ (nabilone)) — NEMA Research, Inc.. Nabilone is a synthetic cannabinoid that mimics THC and binds to cannabinoid receptors in the central nervous system to reduce nausea and vomiting.

Comparator set (3 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Cesamet™ (nabilone) TARGET	Cesamet™ (nabilone)	NEMA Research, Inc.	marketed	Synthetic cannabinoid	CB1 and CB2 cannabinoid receptors
Nabilone Oral Capsule	Nabilone Oral Capsule	Centre for Addiction and Mental Health	marketed	Synthetic cannabinoid	CB1 and CB2 cannabinoid receptors
Nabilone, flexible dosing	Nabilone, flexible dosing	University of Calgary	phase 3	Synthetic cannabinoid	CB1 and CB2 cannabinoid receptors
Nabilone Capsules	Nabilone Capsules	Eldon Loh, MD	phase 3	Synthetic cannabinoid	CB1 receptor, CB2 receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Synthetic cannabinoid class)

1. Centre for Addiction and Mental Health · 1 drug in this class
2. Eldon Loh, MD · 1 drug in this class
3. NEMA Research, Inc. · 1 drug in this class
4. University of Calgary · 1 drug in this class